For More Information
- HER2 Support Group
- Breast Cancer Treatment
- Guide For Women
- Metastatic Breast Cancer
- Sources of Support
- Nutrition & Physical Activity
- NCI Publications
- Follow-Up Care
- Complimentary & Alternative Medicine
- Breast Reconstruction
- Risk Factors
- Cancer & Cancer Pathways
- MD Anderson Cancer Handbook
- Your Guide to Cancer Care
- How To Handle The Fear of Breast Cancer
Oncotype DX is a test that examines a breast cancer patient's tumor tissue at a molecular level, and gives information about her individual disease. This information can help tailor treatment for her breast cancer.
WHEN TEST WOULD BE PERFORMED
The Oncotype DX assay is intended to be used by women with early-stage (Stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.
The Oncotype DX® test is a diagnostic test that helps identify which women with early-stage, estrogen-receptor-positive and lymph-node-negative breast cancer are more likely to benefit from adding chemotherapy to their hormonal treatment. This test also helps assess the likelihood that an individual woman's breast cancer will return. The Oncotype DX test provides important information that you and your doctor may use when making decisions about treatment. Post-menopausal women recently diagnosed with node-positive, hormone-receptor-positive breast cancer may also be appropriate candidates for the Oncotype DX test.
|Last Updated on Thursday, 21 January 2010 10:08|